These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11889264)

  • 21. The future of pharmacogenetics in Parkinson's disease treatment.
    Hutz MH; Rieder CR
    Pharmacogenomics; 2018 Feb; 19(3):171-174. PubMed ID: 29191064
    [No Abstract]   [Full Text] [Related]  

  • 22. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
    Paus S; Grünewald A; Klein C; Knapp M; Zimprich A; Janetzky B; Möller JC; Klockgether T; Wüllner U
    Mov Disord; 2008 Mar; 23(4):599-602. PubMed ID: 18175338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease.
    Black KJ; Hershey T; Hartlein JM; Carl JL; Perlmutter JS
    Neuropsychopharmacology; 2005 Mar; 30(3):590-601. PubMed ID: 15602502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine D3 and D4 receptor gene polymorphisms and Parkinson's disease.
    Nanko S; Hattori M; Ueki A; Ikeda K
    Lancet; 1993 Jul; 342(8865):250. PubMed ID: 8100976
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
    Simms SL; Huettner DP; Kortagere S
    Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine receptors, motor responses, and dopaminergic agonists.
    Luquin-Piudo MR; Sanz P
    Neurologist; 2011 Nov; 17(6 Suppl 1):S2-8. PubMed ID: 22045321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
    Rieck M; Schumacher-Schuh AF; Altmann V; Francisconi CL; Fagundes PT; Monte TL; Callegari-Jacques SM; Rieder CR; Hutz MH
    Pharmacogenomics; 2012 Nov; 13(15):1701-10. PubMed ID: 23171335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG
    Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa strengths and weaknesses.
    Jankovic J
    Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
    Pizzolato G; Cagnin A; Rossato A; Chierichetti F; Fabbri M; Dam M; Ferlin G; Battistin L
    Adv Neurol; 1996; 69():467-73. PubMed ID: 8615167
    [No Abstract]   [Full Text] [Related]  

  • 36. Levodopa and the progression of Parkinson's disease.
    Walton-Hadlock JL
    N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
    Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
    Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease.
    Kaasinen V; Någren K; Hietala J; Oikonen V; Vilkman H; Farde L; Halldin C; Rinne JO
    Neurology; 2000 Apr; 54(7):1482-7. PubMed ID: 10751262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease.
    Eryilmaz IE; Erer S; Zarifoglu M; Egeli U; Karakus E; Yurdacan B; Cecener G; Tunca B; Colakoglu B; Bora Tokcaer A; Saka E; Demirkiran M; Akbostanci C; Dogu O; Kaleagasi H; Kenangil G; Cakmur R; Elibol B
    Clin Neurol Neurosurg; 2020 Dec; 199():106257. PubMed ID: 33039854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.